Baidu
map

Braz J Otorhinolaryngol:后鼻神经切除术在过敏性鼻炎患者中的长期结果

2021-06-22 AlexYang MedSci原创

过敏性鼻炎(AR)是一种免疫球蛋白E(IgE)介导的鼻粘膜炎症,对特定的过敏原产生反应,导致的症状包括瘙痒、鼻塞、水样鼻涕,以及在没有感染时打喷嚏。AR患者还可能有眼部症状、慢性咳嗽和鼻后滴漏,大大降

过敏性鼻炎(AR)是一种免疫球蛋白E(IgE)介导的鼻粘膜炎症,对特定的过敏原产生反应,导致的症状包括瘙痒、鼻塞、水样鼻涕,以及在没有感染时打喷嚏。AR患者还可能有眼部症状、慢性咳嗽和鼻后滴漏,大大降低了一部分患者的生活质量。AR的一线治疗通常包括使用第二代非镇静性抗组胺药和鼻内类固醇。对于那些对药物治疗没有表现出满意反应的患者,皮下或舌下过敏原特异性免疫疗法通常可以有效地缓解症状。

近期,有研究人员比较了后鼻神经切除术(有或没有咽丛神经切除术)对治疗中度至重度常年性过敏性鼻炎的临床疗效。次要的研究目的包括比较这两种手术治疗组的患者的并发症的严重程度,包括慢性咳嗽和哮喘。

共有52名患者参加了这项随机对照试验,并分配到对照组(后鼻神经切除术)或实验组(后鼻神经切除术+咽部神经切除术)。视觉模拟量表和鼻结膜炎生活质量调查表用来比较基线和治疗后6、12和24个月之间患者症状的差异。此外,在随访期间,研究人员分别通过视觉模拟量表和哮喘控制测试监测患者的咳嗽和哮喘症状。

结果发现,各组之间的术前评分没有明显的差异(P>0.05)。治疗后6个月,实验组和对照组患者的视觉模拟量表、鼻结膜炎生活质量调查表和哮喘控制测试得分相对于基线值有明显差异(P<0.05),并在第12个月和第24个月的随访中得以保持。在术后任何一个随访时间点,两组治疗患者的视觉模拟量表、鼻结膜炎生活质量调查表或哮喘控制测试得分均无明显差异(P>0.05),但实验组的咳嗽严重程度相对于对照组明显降低(P<0.05)。

试验组和对照组的VAS得分均值情况

综上所述,后鼻神经切除术可以有效地治疗过敏性鼻炎,也可以不进行咽部神经切除术。在治疗过敏性鼻炎患者的慢性咳嗽方面,后鼻神经切除术和咽神经切除术联合治疗可能比单纯的后鼻神经切除术效果更好

原始出处:

Hongting Hua, Guoyuan Wang, Yi Zhao et al. The long-term outcomes of posterior nasal neurectomy with or without pharyngeal neurectomy in patients with allergic rhinitis: a randomized controlled trial. Braz J Otorhinolaryngol. May 2021

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1723774, encodeId=cecf1e23774e6, content=<a href='/topic/show?id=ac899e0343c' target=_blank style='color:#2F92EE;'>#长期结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97034, encryptionId=ac899e0343c, topicName=长期结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee6a33536665, createdName=zhucaizhong7777, createdTime=Tue Feb 22 06:43:03 CST 2022, time=2022-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714917, encodeId=e92a1e1491743, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Thu Jan 27 18:43:03 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047422, encodeId=4df8204e422d6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 20 11:43:03 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877439, encodeId=471018e743957, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Sep 18 08:43:03 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975985, encodeId=1e8e9e598582, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jun 22 23:58:58 CST 2021, time=2021-06-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1723774, encodeId=cecf1e23774e6, content=<a href='/topic/show?id=ac899e0343c' target=_blank style='color:#2F92EE;'>#长期结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97034, encryptionId=ac899e0343c, topicName=长期结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee6a33536665, createdName=zhucaizhong7777, createdTime=Tue Feb 22 06:43:03 CST 2022, time=2022-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714917, encodeId=e92a1e1491743, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Thu Jan 27 18:43:03 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047422, encodeId=4df8204e422d6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 20 11:43:03 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877439, encodeId=471018e743957, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Sep 18 08:43:03 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975985, encodeId=1e8e9e598582, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jun 22 23:58:58 CST 2021, time=2021-06-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1723774, encodeId=cecf1e23774e6, content=<a href='/topic/show?id=ac899e0343c' target=_blank style='color:#2F92EE;'>#长期结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97034, encryptionId=ac899e0343c, topicName=长期结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee6a33536665, createdName=zhucaizhong7777, createdTime=Tue Feb 22 06:43:03 CST 2022, time=2022-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714917, encodeId=e92a1e1491743, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Thu Jan 27 18:43:03 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047422, encodeId=4df8204e422d6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 20 11:43:03 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877439, encodeId=471018e743957, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Sep 18 08:43:03 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975985, encodeId=1e8e9e598582, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jun 22 23:58:58 CST 2021, time=2021-06-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1723774, encodeId=cecf1e23774e6, content=<a href='/topic/show?id=ac899e0343c' target=_blank style='color:#2F92EE;'>#长期结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97034, encryptionId=ac899e0343c, topicName=长期结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee6a33536665, createdName=zhucaizhong7777, createdTime=Tue Feb 22 06:43:03 CST 2022, time=2022-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714917, encodeId=e92a1e1491743, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Thu Jan 27 18:43:03 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047422, encodeId=4df8204e422d6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 20 11:43:03 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877439, encodeId=471018e743957, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Sep 18 08:43:03 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975985, encodeId=1e8e9e598582, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jun 22 23:58:58 CST 2021, time=2021-06-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1723774, encodeId=cecf1e23774e6, content=<a href='/topic/show?id=ac899e0343c' target=_blank style='color:#2F92EE;'>#长期结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97034, encryptionId=ac899e0343c, topicName=长期结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee6a33536665, createdName=zhucaizhong7777, createdTime=Tue Feb 22 06:43:03 CST 2022, time=2022-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714917, encodeId=e92a1e1491743, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Thu Jan 27 18:43:03 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047422, encodeId=4df8204e422d6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 20 11:43:03 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877439, encodeId=471018e743957, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Sep 18 08:43:03 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975985, encodeId=1e8e9e598582, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jun 22 23:58:58 CST 2021, time=2021-06-22, status=1, ipAttribution=)]
    2021-06-22 wxl882001

    了解

    0

相关资讯

Int Arch Allergy Immunol:鼻内镜在过敏性鼻炎和屋尘螨舌下免疫疗法中的作用

在过去的30年里,舌下免疫疗法(SLIT)被广泛认为是治疗过敏性鼻炎(AR)的一种安全有效的治疗方式,能够改变过敏性疾病的自然进程。在评估SLIT疗效的众多方法中,主观评估,如鼻部症状总分(TNSS)

Am J Otolaryngol:过敏性鼻炎影响鼻腔手术成功率

阻塞性睡眠呼吸暂停(OSA)的特点是上呼吸道多层次的气道阻塞。鼻子在上呼吸道的总阻力中贡献率占50%以上;鼻腔呼吸具有重要的生理功能,包括加湿、加热和过滤。鼻腔阻塞在OSA患者中很常见;它导致睡眠结构

Ann Allergy Asthma Immunol:氯雷他定-伪麻黄碱和氟替卡松鼻喷雾剂治疗过敏性鼻炎的鼻腔气流比较

过敏性鼻炎是世界上最普遍的疾病之一,影响到全球高达30%的人。在患有季节性变应性鼻炎的个体中,吸入性过敏原如豚草、草和树花粉能够引起免疫球蛋白E (IgE)介导的反应。这种反应涉及炎症介质的释放,引起

盘点:近期过敏性鼻炎的免疫治疗进展

【1】J Allergy Clin Immunol:猫尾草皮下和舌下免疫疗法对过敏原特异性IgA反应的不同诱导作用

Ann Allergy Asthma Immunol:SLIT片剂治疗过敏性鼻炎的进展分析

过敏性鼻炎(AR)可以与结膜炎(C)同时发生,是一种IgE介导的炎症,会引起打喷嚏、鼻塞、鼻出血和鼻痒症状。据估计,受AR的影响的人群比例为10-30%,且AR对生活质量有相当大的影响。在临床实践中可

Int Arch Allergy Immunol:过敏性鼻炎患者中虾过敏的临床相关性研究

在热带地区,屋尘螨(HDM)致敏是呼吸道过敏(如哮喘和鼻炎)发展的一个主要风险因素。另一方面,虾是食物过敏的最重要来源之一,经常与IgE介导的超敏反应有关。有一些过敏原在结构上具有同源性,属于同一类蛋

Baidu
map
Baidu
map
Baidu
map